According to a phase 3 trial, the investigational anti–IL-17A IgG1 monoclonal antibody, #SSGJ608 showed "rapid and robust" clinical response among patients with moderate-to-severe #psoriasis. #PsO #Dermatology

www.docwirenews.com/post/investi...